Ozempic and other GLP-1 agonists supply
April 2024 update:
Ozempic:
- Novo Nordisk has advised that all doses of Ozempic are now available across Canada and the supply situation is currently stable.
- They are no longer encouraging pharmacists to limit prescriptions to a 30-day supply, indicating that patients can now fill a 90-day prescription.
Mounjaro/Trulicity:
- Due to continued demand, there continues to be shortages of Trulicity (dulaglutide) and Mounjaro (tirzepatide) and allocation strategies have been implemented.
- The manufacturer is encouraging pharmacists to continue to limit refill prescriptions to a 30-day supply.
More info: Update on the supply of Ozempic and other GLP-1 receptor agonists: Notice
Products impacted
Ozempic
Novo Nordisk reports that the shortage for both Ozempic dose strengths are now resolved and the supply/demand situation for all dose strengths is stable.
|
Ozempic® 1 mg pen (DIN: 02471469) |
Updated to resolved on January 18, 2024 More info: View shortage report. |
| Ozempic® 0.25/0.5 mg pen – 1.5mL(DIN: 02471477) |
Updated to resolved on February 17, 2024 More info: View shortage report. |
| Ozempic® 0.25/0.5 mg – 3mL pen (DIN: 02540258 ) |
Other products
Eli Lilly has advised Health Canada that, depending on the strength of the dosage, it expects shortages to end on May 31, 2024, for Trulicity (dulaglutide) and between June 1 and July 1, 2024, for Mounjaro (tirzepatide).
|
Mounjaro® |
Shortage due to demand increase. |
|
Trulicity® |
Shortage due to demand increase. |
Related links
- Update on the supply of Ozempic and other GLP-1 receptor agonists: Notice
- Notice: Recommendations while Ozempic and other GLP-1 agonists are in shortage
Interested in helping CPhA combat drug shortages?
Join the Pharmacy Virtual Advisory Team.
Last updated: April 12, 2024
Did you find this information helpful?
